This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 22/7/1552    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Google Scholar Articles by Paulmurugan, R. Articles by Gambhir, S. S. PubMed PubMed Citation Articles by Paulmurugan, R. Articles by Gambhir, S. S.

A Human Estrogen Receptor (ER) Mutation with Differential Responsiveness to Nonsteroidal Ligands: Novel Approaches for Studying Mechanism of ER Action

Departments of Radiology and Bioengineering (R.P., S.S.G.), Bio-X Program, Molecular Imaging Program at Stanford), Stanford University School of Medicine, Stanford, California 94305-5427; and Departments of Chemistry (A.T., J.A.K.) and Molecular and Integrative Physiology (B.S.K.), University of Illinois at Champaign-Urbana, Urbana, Illinois 61801

Address all correspondence and requests for reprints to: Ramasamy Paulmurugan, Stanford University School of Medicine, James H. Clark Center, 318 Campus Drive, 150 East Wing, First Floor, Stanford, California 94305-5427. E-mail: paulmur8{at}stanford.edu.

Estrogens, acting through the estrogen receptors (ERs), play crucial roles in regulating the function of reproductive and other systems under physiological and pathological conditions. ER activity in regulating target genes is modulated by the binding of both steroidal and synthetic nonsteroidal ligands, with ligand binding inducing ERs to adopt various conformations that control their interactions with transcriptional coregulators. Previously, we developed an intramolecular folding sensor with a mutant form of ER (ER_G521T) that proved to be essentially unresponsive to the endogenous ligand 17β-estradiol, yet responded very well to certain synthetic ligands. In this study, we have characterized this G521T-ER mutation in terms of the potency and efficacy of receptor response toward several steroidal and nonsteroidal ligands in two different ways: directly, by ligand effects on mutant ER conformation (by the split-luciferase complementation system), and indirectly, by ligand effects on mutant ER transactivation. Full-length G521T-ER shows no affinity for estradiol and does not activate an estrogen-responsive reporter gene. The synthetic pyrazole agonist ligand propyl-pyrazole-triol is approximately 100-fold more potent than estradiol in inducing intramolecular folding and reporter gene transactivation with the mutant ER, whereas both ligands have high potency on wild-type ER. This estradiol-unresponsive mutant ER can also specifically highlight the agonistic property of the selective ER modulator, 4-hydroxytamoxifen, by reporter gene transactivation, even in the presence of estradiol, and it can exert a dominant-negative effect on estrogen-stimulated wild-type ER. This system provides a model for ER-mutants that show differential ligand responsiveness to gene activation to gain insight into the phenomenon of hormone resistance observed in endocrine therapies of ER-positive breast cancers.

NURSA Molecule Pages Link:

Nuclear Receptors:   ERα  |  ERβ

Ligands:   17β-Estradiol  |  Diethylstilbestrol  |  4-Hydroxytamoxifen  |  Raloxifene